Recent merger opposes biosimilar prevalence in marketplace.
Alexandra
A
Sklan
D004345:Drug Industry / Q000191:economics*; D006273:Health Facility Merger; D006961:Hyperparathyroidism / Q000188:drug therapy / Q000209:etiology; D007676:Kidney Failure, Chronic / Q000150:complications; D010455:Peptides / Q000627:therapeutic use
D010455:Peptides